Top

Published in:

01-07-2018 | Original Article

Randomized double-blind clinical trial of combined treatment with megestrol acetate plus celecoxib versus megestrol acetate alone in cachexia-anorexia syndrome induced by GI cancers

Published in: Supportive Care in Cancer | Issue 7/2018

Abstract

Purpose

Previous studies reported promising efficacy for celecoxib in the treatment of cancer cachexia. We designed this study to test the hypothesis that combination therapy with megestrol acetate (MA) plus celecoxib is superior to MA alone.

Methods

Ninety eligible gastrointestinal cancer patients randomly received either MA 320 mg/day plus placebo (arm1) or MA 320 mg/day plus celecoxib 200 mg/day (arm2). Patients were evaluated at baseline, then 1 and 2 months after starting interventions. The primary outcome was body weight. Secondary outcomes were quality of life, grip strength, appetite score, performance status, plasma albumin, CRP, IL-6, and Glasgow Prognostic Score.

Results

Patients were comparable at baseline. Sixty patients were assessable for the first month and 33 patients for the second month. After 2 months, patients in arm1 (MA + placebo) and arm2 (MA + celecoxib) experienced 4.0 ± 3.4 and 2.2 ± 3.6Kg of weight gain respectively (P = 0.163). Changes relative to baseline were statistically significant in both arms of the study (P = 0.001). Regarding secondary outcomes, comparisons between groups did not show any statistically significant difference, but within-group changes were significant in both arms of the study.

Conclusion

Since both MA alone and MA plus celecoxib are associated with improvement of cachexia in GI cancer patients, this study failed to show that adding celecoxib (200 mg/day) to megestrol (320 mg/day) could enhance anti-cachexic effects of megestrol.

Available only for authorised users

Hopkinson JB (2014) Psychosocial impact of cancer cachexia. J Cachexia Sarcopenia Muscle 5(2):89–94. https://doi.org/10.1007/s13539-014-0142-1 CrossRefPubMedPubMedCentral

Fearon KC, Glass DJ, Guttridge DC (2012) Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 16(2):153–166. https://doi.org/10.1016/j.cmet.2012.06.011 CrossRefPubMed

Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD (2008) Cachexia: a new definition. Clin Nutr (Edinburgh, Scotland) 27(6):793–799. https://doi.org/10.1016/j.clnu.2008.06.013 CrossRef

Ruiz Garcia V, Lopez-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S (2013) Megestrol acetate for treatment of anorexia-cachexia syndrome. The Cochrane database of systematic reviews (3):Cd004310.https://doi.org/10.1002/14651858.CD004310.pub3

Deans DA, Tan BH, Wigmore SJ, Ross JA, de Beaux AC, Paterson-Brown S, Fearon KC (2009) The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer. Br J Cancer 100(1):63–69. https://doi.org/10.1038/sj.bjc.6604828 CrossRefPubMedPubMedCentral

McMillan DC (2009) Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12 (3):223–226. https://doi.org/10.1097/MCO.0b013e32832a7902

Rothwell NJ (1992) Eicosanoids, thermogenesis and thermoregulation. Prostaglandins Leukot Essent Fat Acids 46(1):1–7. https://doi.org/10.1016/0952-3278(92)90051-J CrossRef

McCarthy DO, Whitney P, Hitt A, Al-Majid S (2004) Indomethacin and ibuprofen preserve gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma. Res Nurs Health 27(3):174–184. https://doi.org/10.1002/nur.20019 CrossRefPubMed

Davis TW, Zweifel BS, O'Neal JM, Heuvelman DM, Abegg AL, Hendrich TO, Masferrer JL (2004) Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting. J Pharmacol Exp Ther 308(3):929–934. https://doi.org/10.1124/jpet.103.063099 CrossRefPubMed

10.

Lai V, George J, Richey L, Kim HJ, Cannon T, Shores C, Couch M (2008) Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head Neck 30(1):67–74. https://doi.org/10.1002/hed.20662 CrossRefPubMed

11.

Mantovani G, Maccio A, Madeddu C, Serpe R, Antoni G, Massa E, Dessi M, Panzone F (2010) Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med (Berlin, Germany) 88(1):85–92. https://doi.org/10.1007/s00109-009-0547-z CrossRef

12.

Madeddu C, Maccio A, Mantovani G (2012) Multitargeted treatment of cancer cachexia. Crit Rev Oncog 17(3):305–314. https://doi.org/10.1615/CritRevOncog.v17.i3.80 CrossRefPubMed

13.

Madeddu C, Dessi M, Panzone F, Serpe R, Antoni G, Cau MC, Montaldo L, Mela Q, Mura M, Astara G, Tanca FM, Maccio A, Mantovani G (2012) Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib +/− megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clin Nutr (Edinburgh, Scotland) 31(2):176–182. https://doi.org/10.1016/j.clnu.2011.10.005 CrossRef

14.

Maccio A, Madeddu C, Gramignano G, Mulas C, Floris C, Sanna E, Cau MC, Panzone F, Mantovani G (2012) A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol 124(3):417–425. https://doi.org/10.1016/j.ygyno.2011.12.435 CrossRefPubMed

15.

Mantovani G, Maccio A, Madeddu C, Serpe R, Massa E, Dessi M, Panzone F, Contu P (2010) Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 15(2):200–211. https://doi.org/10.1634/theoncologist.2009-0153 CrossRefPubMedPubMedCentral

16.

Mantovani G, Maccio A, Madeddu C, Gramignano G, Lusso MR, Serpe R, Massa E, Astara G, Deiana L (2006) A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiology, Biomarkers & Prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 15 (5):1030–1034.https://doi.org/10.1158/1055-9965.epi-05-0538

17.

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489–495. https://doi.org/10.1016/s1470-2045(10)70218-7 CrossRefPubMed

18.

Inui A (2005) Recent development in research and management of cancer anorexia-cachexia syndrome. Gan to Kagaku Ryoho Cancer Chemother 32(6):743–749

19.

Muscaritoli M, Anker SD, Argiles J, Aversa Z, Bauer JM, Biolo G, Boirie Y, Bosaeus I, Cederholm T, Costelli P, Fearon KC, Laviano A, Maggio M, Rossi Fanelli F, Schneider SM, Schols A, Sieber CC (2010) Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr (Edinburgh, Scotland) 29(2):154–159. https://doi.org/10.1016/j.clnu.2009.12.004 CrossRef

20.

Argiles JM, Lopez-Soriano FJ, Toledo M, Betancourt A, Serpe R, Busquets S (2011) The cachexia score (CASCO): a new tool for staging cachectic cancer patients. J Cachexia Sarcopenia Muscle 2(2):87–93. https://doi.org/10.1007/s13539-011-0027-5 CrossRefPubMedPubMedCentral

21.

Vigano AAL, Morais JA, Ciutto L, Rosenthall L, di Tomasso J, Khan S, Olders H, Borod M, Kilgour RD (2017) Use of routinely available clinical, nutritional, and functional criteria to classify cachexia in advanced cancer patients. Clin Nutr (Edinburgh, Scotland) 36(5):1378–1390. https://doi.org/10.1016/j.clnu.2016.09.008 CrossRef

22.

LeBlanc TW, Nipp RD, Rushing CN, Samsa GP, Locke SC, Kamal AH, Cella DF, Abernethy AP (2015) Correlation between the international consensus definition of the cancer anorexia-cachexia syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer. J Pain Symptom Manag 49(4):680–689. https://doi.org/10.1016/j.jpainsymman.2014.09.008 CrossRef

23.

Blum D, Stene GB, Solheim TS, Fayers P, Hjermstad MJ, Baracos VE, Fearon K, Strasser F, Kaasa S (2014) Validation of the consensus-definition for cancer cachexia and evaluation of a classification model—a study based on data from an international multicentre project (EPCRC-CSA). Ann Oncol 25(8):1635–1642. https://doi.org/10.1093/annonc/mdu086 CrossRefPubMed

24.

Wallengren O, Lundholm K, Bosaeus I (2013) Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer : Off J Multinatl Assoc Support Care Cancer 21(6):1569–1577. https://doi.org/10.1007/s00520-012-1697-z CrossRef

25.

Gebbia V, Testa A, Gebbia N (1996) Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer. Br J Cancer 73(12):1576–1580. https://doi.org/10.1038/bjc.1996.297 CrossRefPubMedPubMedCentral

26.

De Conno F, Martini C, Zecca E, Balzarini A, Venturino P, Groff L, Caraceni A (1998) Megestrol acetate for anorexia in patients with far-advanced cancer: a double-blind controlled clinical trial. Eur J Cancer 34(11):1705–1709. https://doi.org/10.1016/S0959-8049(98)00219-6 CrossRefPubMed

27.

Loprinzi CL, Bernath AM, Schaid DJ, Malliard JA, Athmann LM, Michalak JC, Tschetter LK, Hatfield AK, Morton RF (1994) Phase III evaluation of 4 doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Oncology 51(Suppl 1):2–7. https://doi.org/10.1159/000227407 CrossRefPubMed

28.

Vadell C, Segui MA, Gimenez-Arnau JM, Morales S, Cirera L, Bestit I, Batiste E, Blanco R, Jolis L, Boleda M, Anton I (1998) Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. Am J Clin Oncol 21(4):347–351. https://doi.org/10.1097/00000421-199808000-00006 CrossRefPubMed

29.

Ulutin HC, Arpaci F, Pak Y (2002) Megestrol acetate for cachexia and anorexia in advanced non-small cell lung cancer: a randomized study comparing two different doses. Tumori 88(4):277–280CrossRefPubMed

30.

Savides TJ, Jensen DM, Cohen J, Randall GM, Kovacs TO, Pelayo E, Cheng S, Jensen ME, Hsieh HY (1996) Severe upper gastrointestinal tumor bleeding: endoscopic findings, treatment, and outcome. Endoscopy 28(2):244–248. https://doi.org/10.1055/s-2007-1005436 CrossRefPubMed

31.

Moreno-Otero R, Rodriguez S, Carbo J, Mearin F, Pajares JM (1987) Acute upper gastrointestinal bleeding as primary symptom of gastric carcinoma. J Surg Oncol 36(2):130–133. https://doi.org/10.1002/jso.2930360212 CrossRefPubMed

32.

Mantovani G, Madeddu C, Maccio A, Gramignano G, Lusso MR, Massa E, Astara G, Serpe R (2004) Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidemiol, Biomark Prev : Publ Am Assoc Cancer Res, cosponsored by the American Society of Preventive Oncology 13(10):1651–1659

33.

Hefler-Frischmuth K, Seebacher V, Polterauer S, Tempfer C, Reinthaller A, Hefler L (2010) The inflammation-based modified Glasgow Prognostic Score in patients with vulvar cancer. Eur J Obstet Gynecol Reprod Biol 149(1):102–105. https://doi.org/10.1016/j.ejogrb.2009.12.027 CrossRefPubMed

34.

NCI, NIH, DHHS (May 29, 2009) common terminology criteria for adverse events v4.0 vol 09-5410. NIH publication United States

35.

McMillan DC, Wigmore SJ, Fearon KC, O'Gorman P, Wright CE, McArdle CS (1999) A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 79(3–4):495–500. https://doi.org/10.1038/sj.bjc.6690077 CrossRefPubMedPubMedCentral

36.

Cerchietti LC, Navigante AH, Peluffo GD, Diament MJ, Stillitani I, Klein SA, Cabalar ME (2004) Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. J Pain Symptom Manag 27(1):85–95. https://doi.org/10.1016/j.jpainsymman.2003.05.010 CrossRef

37.

von Haehling S, Anker SD (2010) Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle 1(1):1–5. https://doi.org/10.1007/s13539-010-0002-6 CrossRef

38.

Tuca A, Jimenez-Fonseca P, Gascon P (2013) Clinical evaluation and optimal management of cancer cachexia. Crit Rev Oncol Hematol 88(3):625–636. https://doi.org/10.1016/j.critrevonc.2013.07.015 CrossRefPubMed

39.

Rogers ES, MacLeod RD, Stewart J, Bird SP, Keogh JW (2011) A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients—ACCeRT study. BMC Cancer 11(1):493. https://doi.org/10.1186/1471-2407-11-493 CrossRefPubMedPubMedCentral

40.

Cohen JS (2005) How celecoxib could be safer, how valdecoxib might have been. Ann Pharmacother 39(9):1542–1545. https://doi.org/10.1345/aph.1G175 CrossRefPubMed

41.

Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM, Eisen GM, Stenson WF, Triadafilopoulos G (2006) Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med 119(3):255–266. https://doi.org/10.1016/j.amjmed.2005.09.054 CrossRefPubMed

42.

de Souza CO, Kurauti MA, de Fatima Silva F, de Morais H, Borba-Murad GR, de Andrade FG, de Souza HM (2015) Effects of celecoxib and ibuprofen on metabolic disorders induced by Walker-256 tumor in rats. Mol Cell Biochem 399(1–2):237–246. https://doi.org/10.1007/s11010-014-2250-9 CrossRefPubMed

43.

Buskermolen S, Langius JA, Kruizenga HM, Ligthart-Melis GC, Heymans MW, Verheul HM (2012) Weight loss of 5% or more predicts loss of fat-free mass during palliative chemotherapy in patients with advanced cancer: a pilot study. Nutr Cancer 64(6):826–832. https://doi.org/10.1080/01635581.2012.690062 CrossRefPubMed

44.

Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM (2005) Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54(4):540–545. https://doi.org/10.1136/gut.2004.047563 CrossRefPubMedPubMedCentral

45.

Ordu C, Pilanci KN, Koksal UI, Okutur K, Saglam S, Tecimer C, Demir G (2014) Can megestrol acetate induce thrombosis in advanced oncology patients receiving chemotherapy? Asian Pac J Cancer Prev : APJCP 15(23):10165–10169CrossRefPubMed

Title: Randomized double-blind clinical trial of combined treatment with megestrol acetate plus celecoxib versus megestrol acetate alone in cachexia-anorexia syndrome induced by GI cancers
Publication date: 01-07-2018
Published in: Supportive Care in Cancer / Issue 7/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4047-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2018

Survivorship care models for breast cancer, colorectal cancer, and adolescent and young adult (AYA) cancer survivors: a systematic review

Enhancing evaluation of sarcopenia in patients with non-small cell lung cancer (NSCLC) by assessing skeletal muscle index (SMI) at the first lumbar (L1) level on routine chest computed tomography (CT)

Exercise capacity and cancer-specific quality of life following curative intent treatment of stage I–IIIA lung cancer

Impaired skeletal muscle oxygenation following allogeneic hematopoietic stem cell transplantation is associated with exercise capacity

Physical activity barriers, preferences, and beliefs in childhood cancer patients

Head and neck cancer patient experience of a new dietitian-delivered health behaviour intervention: ‘you know you have to eat to survive’

Keynote webinar | Spotlight on antibody–drug conjugates in cancer